“These four look like solid picks for more aggressive growth investors as they have significant catalysts that can drive growth for the rest of 2021 and beyond,” says the author of today’s article in regards to the four stocks he proceeds to highlight, each of which is a top growth stock call for 2021 from Jefferies. For these four stocks – which include a company that could benefit from the rollout of COVID-19 vaccines – CLICK HERE.
One of the strongest biotechs out there, a diamond in the rough, and a high-risk, high-reward play make up the three biotech stocks identified by the author of today’s article as top picks for 2021 for investors looking for even better biotech returns than those offered by broad biotech ETFs such as the SPDR S&P Biotech ETF. For a look at these three biotech stocks, CLICK HERE.
While biotech stocks have been hot over the last year, today’s article notes that another group of stocks have been trading like biotech companies of late: psychedelic stocks. In fact, a slew of psychedelic stocks have posted triple-digit returns over the last year – and with the impending release of studies examining the use of psychedelics to treat mental health disorders, the “shroom boom” may just be beginning. For more, CLICK HERE.
While many are hopeful that 2021 will bring better times than 2020, there’s much we don’t know about what this new year has in store. One thing we do know, points out the author of today’s article, is that “there will be new problems needing more tech, and tech investors are ever-ready to pounce when that time comes.” As such, he proceeds to take a look at what may be three of the best tech stocks to watch right now. For these three stocks, CLICK HERE.
The thing that created the conditions that made 2020 so awful for so many – the coronavirus pandemic – also created the conditions for tech to stage an impressive rally. The three promising tech stocks highlighted in today’s article, however, did not participate in that rally. As a result, these underperforming stocks “still trade at levels that leave room for huge growth” and “could turn things around and deliver fantastic returns to shareholders in 2021.” For these three stocks, CLICK HERE.
While the most important decisions made by the FDA in December were undoubtedly the Emergency Use Authorizations for two COVID-19 vaccines, the month also saw a number of firsts on the regulatory front, including the authorization of the first test allowing for at-home collection of patient samples to detect both COVID-19 and influenza A and B. Now, today’s article takes a look at the biotech companies awaiting FDA decisions in January. For more, CLICK HERE.
Noting how difficult it can be for investors to understand what’s happening in the biotech industry generally and at specific biotech companies, the author of today’s article explains that he tends to invest “in companies that have a track record of working with existing products while successfully developing pipelines of new products” and in “picks-and-shovels companies that get paid to sell their products and services to the developers” – and he proceeds to highlight five of his “rational” biotech picks to consider. For more, CLICK HERE.
While the pharma/biotech sector was not spared COVID-19 pain this year, with various companies hit hard by disruptions in clinical studies and delays in elective surgeries and in individuals seeking medical care, the authors of today’s article note that “some biotech stocks have more than doubled during this period, especially those focusing on developing a coronavirus vaccine.” They proceed to look at “six biotech/drug stocks that have managed to perform well so far this year backed by their encouraging progress in developing a coronavirus vaccine.” For more, CLICK HERE.
Compelling clinical trial data and decisions from the FDA could send one, two, or all three of the biotech stocks highlighted in today’s article through the roof next year. For a look at each of these three biotech stocks and their respective catalysts – as well as a consideration of the potential pitfalls associated with each of them – CLICK HERE.
Today’s article highlights “a low-risk, high-quality small biotech with high growth potential.” More specifically, this “is a revolutionary biotech company that uses tissue engineering to treat/repair sports-related injuries and severe burns” – and while it was negatively impacted this year by the canceling and delaying of elective surgeries due to COVID-19, the author outlines why rapid growth should return in 2021. For more, CLICK HERE.